Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials

Belletti, Alessandro; Campochiaro, Corrado; Marmiere, Marilena; Likhvantsev, Valery; Yavorovskiy, Andrey; Dagna, Lorenzo; Landoni, Giovanni; Zangrillo, Alberto; Hajjar, Ludhmila Abrahão

doi:10.1186/s13613-021-00941-2

Annals of Intensive Care

Table 1 Characteristics of included studies

From: Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials

First author	Acronym	Journal	Setting	Trial registration number	Blinding	Treatment	Control
Gordon AC	REMAP-CAP	N Engl J Med	COVID-19 critically ill patients	ClinicalTrials.gov NCT02735707	Open-label	Tocilizumab, sarilumab	Standard care
Hermine O	CORIMUNO-TOCI 1	JAMA Intern Med	COVID-19 moderate/severe pneumonia	ClinicalTrials.gov NCT04331808	Open-label	Tocilizumab	Standard care
Lescure FX	N/A	Lancet Respir Med	COVID-19 severe pneumonia	ClinicalTrials.gov NCT04327388	Double-blind	Sarilumab	Placebo
RECOVERY Collaborative Group	RECOVERY	Lancet	COVID-19 pneumonia (SpO₂ < 92%), elevated CRP	ClinicalTrials.gov NCT04381936	Open-label	Tocilizumab	Standard care
Rosas IO	COVACTA	N Engl J Med	COVID-19 severe pneumonia	ClinicalTrials.gov NCT04320615	Double-blind	Tocilizumab	Placebo
Rutgers A	PreToVid	SSRN Electron J	COVID-19 pneumonia with hyperinflammation	Netherlands Trial Register NL8504	Open-label	Tocilizumab	Standard care
Salama C	EMPACTA	N Engl J Med	COVID-19 pneumonia, not on NIMV/IMV	ClinicalTrials.gov NCT04372186	Double-blind	Tocilizumab	Placebo
Salvarani C	RCT-TCZ-COVID-19	JAMA Intern Med	COVID-19 pneumonia, hyperinflammatory state, not on MV, not in ICU	ClinicalTrials.gov NCT04346355	Open-label	Tocilizumab	Standard care
Sivapalasingam S	N/A	medXriv	COVID-19 pneumonia requiring supplemental oxygen	ClinicalTrials.gov NCT04315298	Double-blind	Sarilumab	Placebo
Soin AS	COVINTOC	Lancet Respir Med	COVID-19 moderate-to-severe pneumonia	Clinical Trials Registry India CTRI/2020/05/025369	Open-label	Tocilizumab	Standard care
Stone JH	BACC Bay Tocilizumab Trial	N Engl J Med	COVID-19 pneumonia, hyperinflammatory state, not on MV	ClinicalTrials.gov NCT04356937	Double-blind	Tocilizumab	Placebo
Talaschian M	N/A	Research Square	COVID-19 pneumonia with elevated CRP/IL-6, not on IMV	Iranian Registry of Clinical Trials IRCT20081027001411N4	Open-label	Tocilizumab	Standard care
Veiga VC	TOCIBRAS	BMJ	COVID-19 severe/critical pneumonia	ClinicalTrials.gov NCT04403685	Open-label	Tocilizumab	Standard care
Wang D	N/A	SSRN Electron J	COVID-19 moderate/severe pneumonia, elevated IL-6	Chinese Clinical Trial Registry ChiCTR2000029765	Open-label	Tocilizumab	Standard care
Zhao H	N/A	Biomed Pharmacother	COVID-19 pneumonia, elevated IL-6	ClinicalTrials.gov NCT04310228	Open-label	Tocilizumab	Favipiravir

COVID-19: coronavirus disease 2019; CRP: C-reactive protein; IL-6: interleukin-6; IMV: invasive mechanical ventilation; MV: mechanical ventilation; N/A: not available; NIMV: non-invasive mechanical ventilation; SpO₂: peripheral oxygen saturation

Back to article page